STOCK TITAN

Director at FibroBiologics (FBLG) receives stock options for 30,803 shares

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

FibroBiologics, Inc. director Richard C. Cilento Jr. reported a grant of stock options. He received options to acquire 30,803 shares of common stock at an exercise price of $0.7503 per share. The options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting and expire on June 22, 2036.

Positive

  • None.

Negative

  • None.
Insider Cilento Richard C. Jr.
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 30,803 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 30,803 shares (Direct)
Footnotes (1)
  1. [object Object]
Option grant size 30,803 shares Stock options to acquire common stock
Exercise price $0.7503 per share Conversion or exercise price of options
Shares underlying options after grant 30,803 shares Total derivative shares following transaction
Option expiration date June 22, 2036 Final exercise date for the stock options
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
conversion or exercise price financial
"conversion_or_exercise_price: 0.7503"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
expiration date financial
"expiration_date: 2036-06-22T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
annual meeting financial
"The options will vest in full upon the earlier of the first anniversary of the date of grant or the date of the next annual meeting."
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did FibroBiologics (FBLG) report for Richard C. Cilento Jr.?

FibroBiologics reported a grant of stock options to director Richard C. Cilento Jr. He received options covering 30,803 shares of common stock as compensation, not an open-market purchase or sale of existing shares.

How many FibroBiologics (FBLG) shares are covered by the new stock options?

The new stock option grant covers 30,803 shares of FibroBiologics common stock. This figure represents the number of shares Mr. Cilento may purchase upon exercise of the options, subject to vesting and the stated expiration date.

What is the exercise price of Richard C. Cilento Jr.’s FibroBiologics (FBLG) options?

The stock options have an exercise price of $0.7503 per share. This is the fixed price at which Mr. Cilento can purchase FibroBiologics common stock once the options vest and before they expire.

When do the new FibroBiologics (FBLG) stock options vest for Richard C. Cilento Jr.?

The options will vest in full on the earlier of the first anniversary of the grant date or the date of FibroBiologics’ next annual meeting, according to the footnote, making vesting time-based rather than performance-based.

When do Richard C. Cilento Jr.’s FibroBiologics (FBLG) stock options expire?

The granted stock options expire on June 22, 2036. After this expiration date, any unexercised portion of the 30,803 options will lapse, and Mr. Cilento will no longer be able to purchase shares under this grant.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cilento Richard C. Jr.

(Last)(First)(Middle)
C/O FIBROBIOLOGICS, INC.
9350 KIRBY DRIVE., SUITE 300

(Street)
HOUSTON, TEXAS 77054

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
FibroBiologics, Inc. [ FBLG ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.750306/23/2026A30,803 (1)06/22/2036Common Stock30,803$030,803D
Explanation of Responses:
1. The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting.
/s/ Ruben A. Garcia, by Power of Attorney06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)